✦ LIBER ✦

Tetrahydroaminoacridine in Alzheimer's disease

✍ Scribed by B. Davies; D. Andrewes; R. Stargatt; D. Ames; V. Tuckwell; S. Davis

Publisher: John Wiley and Sons
Year: 1990
Tongue: English
Weight: 445 KB
Volume: 5
Category: Article
ISSN: 0885-6230
DOI: 10.1002/gps.930050508

No coin nor oath required. For personal study only.

✦ Synopsis

Tetrahydroaminoacridine (THA), a centrally acting anticholinesterase, was used in a two-month, double-blind, placebo-controlled crossover trial to treat 10 patients meeting DSM-111-R criteria for dementia of the Alzheimer type. Eight patients continued to take THA for a further three months. Nausea was a frequent side-effect. Five patients developed abnormal liver function tests; liver biopsies showed evidence of liver cell necrosis in three patients, a granulomatous reaction in one, and one recovered after reduction of THA dosage. During the trial, patients as a group showed a significantly better performance on one of 10 memory tests when taking THA as compared to placebo. One patient showed a marked clinical improvement, six showed some improvement, and three patients showed no improvement with the active treatment. The group of eight patients who completed a further three months of THA treatment showed a significant deterioration on two psychological test scores.

KEY wom-Tetrahydroaminoacridine, Alzheimer's disease, double blind, therapeutic trial.

📜 SIMILAR VOLUMES

ALZHEIMER'S DISEASE IN POLAND

✍ B. SZCZEPANOWSKA 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 2 views

Neuroplasticity in Alzheimer's disease

✍ Bruce Teter; J. Wesson Ashford 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB

## Abstract Ramon y Cajal proclaimed in 1928 that “once development was ended, the founts of growth and regeneration of the axons and dendrites dried up irrevocably. In the adult centers the nerve paths are something fixed, ended and immutable. Everything must die, nothing may be regenerated. It is

Interventions in Alzheimer's disease

✍ Romola S. Bucks; Lucie Byrne; Judy Haworth; Gordon Wilcock; Julia Hyde; Catherin 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 31 KB

## Discussion To date, the mechanism underlying drug-induced hyponatremia remains poorly understood. While some authors have suggested that the phenomenon may be a class effect of the SSRIs (Ball and Herzberg, 1994), others have cautioned that hyponatremia may develop with virtually any antidepres

Presenilin mutations in Alzheimer's dise

Presenilin mutations in Alzheimer's disease

✍ Marc Cruts; Christine Van Broeckhoven 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB 👁 2 views

The presenilins (PS-1 and PS-2) are 2 members of a novel family of genes encoding integral membrane proteins recently implicated in Alzheimer's disease (AD) pathology. To date, 43 mutations have been identified in PS-1 and 2 in PS-2 that lead to familial presenile AD (onset before age 65 years). The

Re-learning in Alzheimer's disease

✍ Jane Winter; Nicola M. Hunkin 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

Shropshire highlighted a lack of action following the detection of abnormal lithium levels (Myers and Hallworth, 1996). There have also been a number of reports regarding ways in which monitoring could be improved. Dedicated lithium clinics have been shown to provide a better standard of monitoring

Decorated plaques in Alzheimer's disease

✍ Takeshi Tabira 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views